OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a Series B financing round. The round was co-led by Qiming Venture Partners and Quan Capital, with participation from Shanghai Science and Technology Innovation Center Equity Investment Fund, Sinopharm Capital, Suzhou Fund, Boquan Equity Investment Management, international investment funds, and existing investor C&D Group.
Funding Use
Proceeds will support the development and commercialization of proof-of-concept (POC) tumor cell therapies, technology platform construction, and the planning and construction of commercialization facilities.
Pipeline Highlights
- Ori-C101: An in-house developed chimeric antigen receptor (CAR)-T therapy targeting GPC3, currently under Investigational New Drug (IND) review in China.
- OriCAR-017: A GPRC5D CAR-T product demonstrating therapeutic potential in the Phase I POLARIS study for relapsed and refractory multiple myeloma (R/R MM).
- OriBS-001 (ATG101): A bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, licensed to Antengene Corporation Ltd (HKEX: 6996). It received tacit clinical trial approval in China in March 2023, following approvals in the U.S. and Australia.-Fineline Info & Tech
